The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADT
Recruiting · NCT06163924 · Observational (researchers observe without assigning treatment) · Lead sponsor: Chinese University of Hong Kong
View the official record on ClinicalTrials.gov →What this trial is about
Prostate cancer is characterised by its slow progression nature, and even for metastatic disease, the 5-year survival is up to 30%. While ADT can effectively control disease, there is increasing evidence suggesting that it can also result in many adverse cardiovascular side effects on the patients, and these effects are particularly important due to the prolonged survival of these patients. There are suggestions that close cardiovascular (CV) monitoring will help to reduce cardiovascular risk and related morbidities. However, there is limited data to show the positive impact of these monitoring could reducing CV risk and morbidities. Moreover, information regarding the optimal follow-up approach and schedule is also lacking. Therefore, there is a need to have more information on the approach to monitoring the CV risk and the real-life impact of this monitoring on our patients. Patients diagnosed with prostate cancer and plan to receive ADT are invited to participate in this study to assess the potential benefit of multidisciplinary care approach to CV risk modification.
Who can take part
Inclusion criteria
- Adult men 18-80 years old
- With histological proven prostate cancer or clinically diagnosed to have prostate cancer,
- Planned for ADT for at least 1 year
Exclusion criteria
- Subjects with established major atherosclerotic cardiovascular disease (ASCVD) as defined by a recent acute coronary syndrome within the past 12 months, a history of myocardial infarction other than the recent acute coronary syndrome event, a history of ischemic stroke, and symptomatic peripheral arterial disease (defined as history of claudication with ankle-brachial index \<0.85 or previous revascularization or amputation
- Prior neoadjuvant or adjuvant hormone therapy within 1 year before
- Refuse or unable to give written informed consent
- Participation in an investigational program with interventions outside of routine clinical practice
Where it is running
1 location listed.
- The Chinese University of Hong Kong - Hong Kong, Hong Kong